{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:59:37Z","timestamp":1785387577101,"version":"3.55.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Drug-related cholangitis has been increasingly recognized in clinical practice; however, the spectrum of implicated agents and their relative contributions remain incompletely characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically identify drugs associated with cholangitis reporting and to characterize disproportionality signals and time-to-onset patterns using a large pharmacovigilance database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were extracted from the FDA Adverse Event Reporting System (FAERS) from the first quarter of 2004 to the second quarter of 2025. Disproportionality analysis was performed using reporting odds ratios (RORs) with 95% confidence intervals (CIs). Significant signals were defined as ROR &amp;gt;1, with the lower bound of the 95% CI &amp;gt; 1, and a Bonferroni correction was applied for multiple comparisons. A case\/non-case design was used for regression analyses. Candidate drugs were selected using the least absolute shrinkage and selection operator (LASSO) regression and further evaluated in a multivariable logistic regression model. Time-to-onset was assessed using descriptive statistics and visualized using distribution plots.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 17,083 reports of drug-related cholangitis were identified. Eighty-four drugs showed significant disproportionality signals, predominantly involving antineoplastic agents, immunomodulators, and antidiabetic drugs. Multivariable analysis identified older age, female sex, and 21 drugs as factors associated with increased reporting odds of cholangitis reporting within the FAERS database. These findings should be interpreted as pharmacovigilance signals intended for hypothesis generation rather than confirmation of causal relationships. The median time to onset was 97 days (interquartile range [IQR], 7\u2013102 days), with most cases occurring within the first 3\u00a0months after treatment initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This large-scale pharmacovigilance study identified multiple drug classes associated with increased reporting odds of cholangitis and demonstrated an early-onset pattern. These findings highlight the importance of clinical vigilance during the initial treatment period and provide a basis for future mechanistic and epidemiological studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1891926","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:21:52Z","timestamp":1785385312000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated pharmacovigilance assessment of drug-associated cholangitis: signal detection, clinical characterization, and mechanistic insights"],"prefix":"10.3389","volume":"17","author":[{"given":"Maohe","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lve","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qujin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengwei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4291\/wjgp.v9.i1.1","article-title":"Acute cholangitis - an update","volume":"9","author":"Ahmed","year":"2018","journal-title":"World J. Gastrointest. Pathophysiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/tri.13852","article-title":"Donor age (\u226545 years) and reduced immunosuppression are associated with the recurrent primary sclerosing cholangitis after liver transplantation - a multicenter retrospective study","volume":"34","author":"Akamatsu","year":"2021","journal-title":"Transpl. Int. Off. J. Eur. Soc. Organ Transpl."},{"key":"B3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1055\/s-0036-1594007","article-title":"The microbiome and primary sclerosing cholangitis","volume":"36","author":"Ali","year":"2016","journal-title":"Semin. Liver Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.gtc.2021.02.005","article-title":"Acute cholangitis: causes, diagnosis, and management","volume":"50","author":"An","year":"2021","journal-title":"Gastroenterol. Clin. North Am."},{"key":"B5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.17235\/reed.2023.9653\/2023","article-title":"Secondary sclerosing cholangitis induced by systemic chemotherapy","volume":"116","author":"Ant\u00f3n Rodriguez","year":"2024","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"B6","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/s12328-022-01651-3","article-title":"Anti programmed death-ligand 1 antibody-related cholangitis without bile duct dilation or stenosis","volume":"15","author":"Azami","year":"2022","journal-title":"Clin. J. Gastroenterol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1385\/IJGC:30:3:147","article-title":"Complications of hepatic artery infusion: a review of 4580 reported cases","volume":"30","author":"Barnett","year":"2001","journal-title":"Int. J. Gastrointest. Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jhep.2021.10.011","article-title":"Long-term sequelae of drug-induced liver injury","volume":"76","author":"Bj\u00f6rnsson","year":"2022","journal-title":"J. Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11894-017-0583-8","article-title":"Secondary sclerosing cholangitis: a review of recent literature","volume":"19","author":"Brooling","year":"2017","journal-title":"Curr. Gastroenterol. Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e437","DOI":"10.1097\/MJT.0000000000001065","article-title":"Potential association of doxycycline with the onset of primary sclerosing cholangitis: a case series","volume":"29","author":"Buness","year":"2022","journal-title":"Am. J. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e20205","DOI":"10.1097\/MD.0000000000020205","article-title":"Risk factors for recurrent autoimmune liver diseases after liver transplantation: a meta-analysis","volume":"99","author":"Chen","year":"2020","journal-title":"Med. Baltim."},{"key":"B52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.beem.2012.11.004","article-title":"History of oral contraceptive drugs and their use worldwide","volume":"27","author":"Christin-Maitre","year":"2013","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"B12","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1001\/jama.293.3.330","article-title":"Effect of estrogen therapy on gallbladder disease","volume":"293","author":"Cirillo","year":"2005","journal-title":"JAMA"},{"key":"B13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1159\/000517270","article-title":"Risk factors for gallstones and cholecystectomy: a large-scale population-based prospective cohort study in Japan","volume":"40","author":"Colvin","year":"2022","journal-title":"Dig. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1097\/MS9.0000000000002169","article-title":"Acute cholangitis: a state-of-the-art review","volume":"86","author":"Cozma","year":"2024","journal-title":"Ann. Med. Surg."},{"key":"B15","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/apt.14540","article-title":"Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis","volume":"47","author":"Damman","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1432-2277.2008.00768.x","article-title":"Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function","volume":"22","author":"De Simone","year":"2009","journal-title":"Transpl. Int. Off. J. Eur. Soc. Organ Transpl."},{"key":"B17","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s11894-001-0015-6","article-title":"Gallbladder sludge: what is its clinical significance?","volume":"3","author":"Ea","year":"2001","journal-title":"Curr. Gastroenterol. Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2019.04.022","article-title":"Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer","volume":"115","author":"Fouchard","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e725","DOI":"10.1210\/clinem\/dgz175","article-title":"GIP and GLP-1 receptor antagonism during a meal in healthy individuals","volume":"105","author":"Gasbjerg","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s10637-017-0484-6","article-title":"A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event","volume":"36","author":"Gelsomino","year":"2018","journal-title":"Invest. New Drugs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7484","DOI":"10.12998\/wjcc.v9.i25.7484","article-title":"Octreotide-induced acute life-threatening gallstones after vicarious contrast medium excretion: a case report","volume":"9","author":"Han","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e068882","DOI":"10.1136\/bmj-2021-068882","article-title":"Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials","volume":"377","author":"He","year":"2022","journal-title":"BMJ"},{"key":"B23","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","article-title":"Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer","volume":"35","author":"Kawakami","year":"2017","journal-title":"Invest. New Drugs"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1148\/rg.2019180213","article-title":"Imaging features of primary sclerosing cholangitis: from diagnosis to liver transplant follow-up","volume":"39","author":"Khoshpouri","year":"2019","journal-title":"Radiogr. Rev. Publ. Radiol. Soc. N. Am. Inc."},{"key":"B25","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1177\/2050640620924274","article-title":"Secondary sclerosing cholangitis in critically ill patients has a poor outcome but lower tumour incidence than primary sclerosing cholangitis","volume":"8","author":"Kirstein","year":"2020","journal-title":"United Eur. Gastroenterol. J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e00136","DOI":"10.14309\/crj.0000000000000136","article-title":"Chemotherapy-induced sclerosing cholangitis caused by systemic chemotherapy","volume":"6","author":"Kusakabe","year":"2019","journal-title":"ACG Case Rep. J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00261-022-03551-z","article-title":"Secondary sclerosing cholangitis: mimics of primary sclerosing cholangitis","volume":"48","author":"Ludwig","year":"2023","journal-title":"Abdom. Radiol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2217\/whe.10.84","article-title":"Drospirenone\/ethinylestradiol: a review on efficacy and noncontraceptive benefits","volume":"7","author":"Machado","year":"2011","journal-title":"Womens Health"},{"key":"B28","doi-asserted-by":"publisher","first-page":"888","DOI":"10.11405\/nisshoshi.112.888","article-title":"A case of secondary sclerosing cholangitis caused by chemotherapy with nab-paclitaxel","volume":"112","author":"Matsuo","year":"2015","journal-title":"Nihon Shokakibyo Gakkai Zasshi = Jpn. J. Gastro-Enterol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0016-5085(89)91575-8","article-title":"Prevalence of gallstone disease in Hispanic populations in the United States","volume":"96","author":"Maurer","year":"1989","journal-title":"Gastroenterology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1097\/CAD.0b013e3283556b9b","article-title":"Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2","volume":"23","author":"Mir","year":"2012","journal-title":"Anti-Cancer Drugs"},{"key":"B31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/jhbp.509","article-title":"Tokyo guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis","volume":"25","author":"Miura","year":"2018","journal-title":"J. Hepato-Biliary-Pancreat. Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1210\/jcem.83.2.4596","article-title":"Comparison of the impact of transdermal versus oral estrogens on biliary markers of gallstone formation in postmenopausal women","volume":"83","author":"Ml","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.21873\/anticanres.13329","article-title":"The efficacy and limitations of postoperative adjuvant chemotherapy in patients with extrahepatic cholangiocarcinoma","volume":"39","author":"Morino","year":"2019","journal-title":"Anticancer Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.2337\/dc19-0415","article-title":"Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial","volume":"42","author":"Nauck","year":"2019","journal-title":"Diabetes Care"},{"key":"B35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3748\/wjg.v26.i3.353","article-title":"Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review","volume":"26","author":"Onoyama","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1210\/jcem-71-6-1658","article-title":"Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly","volume":"71","author":"Pl\u00f6ckinger","year":"1990","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e858","DOI":"10.1097\/MEG.0000000000002280","article-title":"Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management","volume":"33","author":"Pi","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"31602","DOI":"10.1038\/s41598-025-16848-y","article-title":"Distinct safety profiles of albumin-bound nab-paclitaxel and paclitaxel in pancreatic cancer focusing on hematologic and hepatobiliary risks","volume":"15","author":"Qin","year":"2025","journal-title":"Sci. Rep."},{"key":"B54","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/13625180600983082","article-title":"Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome","volume":"12","author":"Pehlivanov","year":"2007","journal-title":"Eur. J. Contracept. Reprod. Health Care"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1080\/00365521.2018.1530297","article-title":"Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs","volume":"53","author":"Rehfeld","year":"2018","journal-title":"Scand. J. Gastroenterol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/pds.615","article-title":"The role of databases in drug postmarketing surveillance","volume":"10","author":"Rodriguez","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B41","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.bpg.2006.05.004","article-title":"Gallstone disease: epidemiology of gallbladder stone disease","volume":"20","author":"Shaffer","year":"2006","journal-title":"Best. Pract. Res. Clin. Gastroenterol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2165\/00044011-200626060-00008","article-title":"Cholelithiasis and thrombosis of the central retinal vein in a renal transplant recipient treated with cyclosporin","volume":"26","author":"Simic","year":"2006","journal-title":"Clin. Drug Invest."},{"key":"B43","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2169\/internalmedicine.5097-20","article-title":"Obstructive jaundice due to duodenal ulcer induced by lenvatinib therapy for hepatocellular carcinoma","volume":"60","author":"Suoh","year":"2021","journal-title":"Intern. Med. (Tokyo Jpn.)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.suc.2018.11.002","article-title":"Cholangitis: causes, diagnosis, and management","volume":"99","author":"Sulzer","year":"2019","journal-title":"Surg. Clin. North Am."},{"key":"B45","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1572-0241.2005.40484.x","article-title":"Mycophenolate mofetil for the treatment of primary sclerosing cholangitis","volume":"100","author":"Talwalkar","year":"2005","journal-title":"Am. J. Gastroenterol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.bbadis.2017.08.033","article-title":"Drug-induced bile duct injury","volume":"1864","author":"Visentin","year":"2018","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000084525","article-title":"Independent risk factors for gallstone formation in a region with high cholelithiasis prevalence","volume":"71","author":"V\u00f6lzke","year":"2005","journal-title":"Digestion"},{"key":"B48","doi-asserted-by":"publisher","first-page":"E153","DOI":"10.1055\/s-0029-1214707","article-title":"Secondary sclerosing cholangitis after chemotherapy with bevacizumab and paclitaxel","volume":"41","author":"von Figura","year":"2009","journal-title":"Endoscopy"},{"key":"B49","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00534-006-1156-7","article-title":"Diagnostic criteria and severity assessment of acute cholangitis: tokyo guidelines","volume":"14","author":"Wada","year":"2007","journal-title":"J. Hepatobiliary. Pancreat. Surg."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e221","DOI":"10.1111\/ajco.13599","article-title":"Combination chemotherapy with NAB\u00ae -paclitaxel and capecitabine for patients with advanced biliary tract cancer (NAP-CAPABIL pilot study)","volume":"18","author":"Woodford","year":"2022","journal-title":"Asia-Pac. J. Clin. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/his.14000","article-title":"Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes","volume":"76","author":"Zen","year":"2020","journal-title":"Histopathology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1891926\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:21:54Z","timestamp":1785385314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1891926\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":54,"alternative-id":["10.3389\/fphar.2026.1891926"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1891926","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"article-number":"1891926"}}